This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Constantine P. Karakousis, MD; Harold O. Douglass, Jr, MD; Peter M. Yeracaris; Edward D. Holyoke, MD

Arch Surg. 1976;111(6):716-718.

Abstract
• Twenty-one patients with malignant melanoma received immunotherapy with BCG. Thirteen patients had adjuvant immunotherapy on a monthly schedule. Of these, eight with regional lymph node metastases (stage III) had been treated by lymphadenectomy. Two of the stage III patients had tumor recurrences within one year, while six are alive and free of melanoma at a median interval of 22 months. The remaining five patients (stage I or II) had level 4 or 5 (Clark classification) primary lesions. Their average tumor-free survival has been 18 months, but there was one regional recurrence in six months.

Eight patients received intralesional treatment with BCG. The extent of local response correlated inversely to the stage of their disease. Higher doses of BCG or multiple simultaneous injections into the same lesion did not produce complete resolution of nodules in patients with far-advanced melanoma. In none was the course altered by intralesional therapy.

(Arch Surg 111:716-718, 1976)

Author Affiliations
From the Department of General Surgery, Roswell Park Memorial Institute, Buffalo, NY.

Footnotes
Accepted for publication Dec 22, 1975.

Reprint requests to Roswell Park Memorial Institute, 666 Elm St, Buffalo, NY 14263 (Dr Karakousis).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?